Financial results for the period ended September 30, 2026
As filed · Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
What happened
FactFinancial results for the period ended September 30, 2026. UN-AUDITED FINANCIAL RESULTS. the unaudited Standalone and Consolidated Financial Results of the Company for the second quarter.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Margins
ContradictedEBITDA for the financial year 2025 stood at INR 506 crores, which represents a growth of 17% on a year-on-year basis.
But in order to reach to the 40%, we need to have the injectable facility and Stellon business.
Change
FactImplication
CapitSignal interpretationMargins
Revisedour operating EBITDA for quarter 4 of this financial year stood at INR 190 crores as compared to INR 134 crores in the same period last year.
EBITDA for the financial year 2025 stood at INR 506 crores, which represents a growth of 17% on a year-on-year basis.
Change
FactImplication
CapitSignal interpretationExports
RevisedAnd for the full financial year, export revenue grew by 12% on a year-on-year basis.
Export revenue grew by an impressive 46% year-on-year, reflecting our strong capabilities in delivering globally compliant products to regulated and semi-regulated markets.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- Backed by the world's largest portfolio of fermentation-based products, best-in-class regulatory compliance, n (management committed by FY27)
- We also expanded our customer base and product portfolio with the addition of new customers and products, stre (management committed by H1 FY27)
Evidence
- Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.(opens the original filing in a new tab)
- Earlier statement · FY25
- Latest statement · Q1 FY27
- Earlier statement · FY25
- Latest statement · FY25
- Earlier statement · FY25
- Latest statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +2 corroborating keywords; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%